Back to search results

Trans-arterial Embolization for Facet Pain

This study is looking at a procedure called trans-arterial embolization (TAE) using Embozene Microspheres to treat pain caused by facet arthropathy (osteoarthritis of the small joints in your spine). Researchers want to see if this procedure is safe and effective for people with ongoing lower back pain from this condition. You might be able to join if you are between 18 and 85 years old, have a confirmed diagnosis of facet arthropathy, and your pain has not improved with other treatments for at least six months. The main goal is to track any serious problems related to the procedure for one year. The study is currently unclear on its recruitment status.

Study design
This is a single-site study involving 40 participants, where everyone receives the same treatment.
What's involved
You will have a spinal angiography and embolization procedure at North Shore University Hospital, followed by 5 hours of monitoring before discharge.
Compensation
Not stated in the trial record.
Follow-up
You will be monitored for serious adverse events for one year after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06965452

Trans-arterial Embolization for the Treatment of Facet Pain Due to Facet Arthropathy

Recruiting
NAAges 18–85InterventionalTreatment
Northwell Health
~40 participants
Updated 2025-08-19 on ClinicalTrials.gov
What's tested:Spinal angiography and embolization/ Embozene Microspheres

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Procedure-Related Serious Adverse Events in the Perioperative Period
Measured over 1 year

Conditions

Facet Joint Arthropathy
Pain
Osteoarthritis

Explore related trials

Arthropathy of spinal facet jointLower Back PainOsteoarthritis

Where it's being run

1 sites across 1 states
New York1

Who to contact

Betsy Moclair
[email protected]
516-253-7753
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-85
Confirmed diagnosis of spinal facet arthropathy on MRI OR CT
Confirmed diagnosis of lumbosacral facetogenic pain based on diagnostic nerve blocks.
Failed medical management of pain.
Back pain persistent for at least 6 months
Pain worse than at least 6/10 on a visual analog pain scale
Failed at least one of either intra-articular injections of steroids/ anesthetics or neuro-ablative procedure.
Maximum of 2 spinal levels of facetogenic pain in the lumbar and sacral spine (i.e. L4-5 and L5-S1).
Modified Rankin Scale 0-2

Exclusion

\- Pregnancy
History of prior spinal embolization at the target level.
History of surgery/ stenting of the aorta at the level of embolization.
Severe allergic reaction to iodinated contrast (i.e. anaphylaxis)
Creatinine \> 1.5 mg/dl and/or creatinine clearance \< 60 mL/min (except if patients is already on hemodialysis).
Modified Rankin Scale \>2
Angiographic/ Procedural Exclusion Criterion: Vascular supply to the spinal cord from the vessels supplying the facet joints targeted for embolization.

What this trial measures

  • Number of Procedure-Related Serious Adverse Events in the Perioperative Period1 year

    The primary outcome measurements for safety are: -The number of procedure-related serious adverse events occurring in the perioperative period